Breaking News

CSL Behring to Acquire uniQure’s Late-Stage Hemophilia B Gene Therapy

AMT-061 program, currently in Phase III trials, could be one of the first gene therapies to provide potentially long-term benefits to patients with hemophilia B

By: Contract Pharma

Contract Pharma Staff

CSL Behring has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of hemophilia B from uniQure. The AMT-061 program, currently in Phase III trials, could be one of the first gene therapies to provide potentially long-term benefits to patients with hemophilia B. One dose of AMT-061 has shown to increase Factor IX (FIX) plasma levels – the blood clotting protein lacking...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters